These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sjögren's and non-Sjögren's sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature. Pucino V; Turner JD; Nayar S; Kollert F; Rauz S; Richards A; Higham J; Poveda-Gallego A; Bowman SJ; Barone F; Fisher BA RMD Open; 2022 May; 8(1):. PubMed ID: 35589331 [TBL] [Abstract][Full Text] [Related]
6. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients. Seror R; Gottenberg JE; Devauchelle-Pensec V; Dubost JJ; Le Guern V; Hayem G; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Morel J; Pedriger A; Puechal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Zarnitsky C; Labetoulle M; Ravaud P; Mariette X Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737 [TBL] [Abstract][Full Text] [Related]
7. Symptom-Based Cluster Analysis Categorizes Sjögren's Disease Subtypes: An International Cohort Study Highlighting Disease Severity and Treatment Discordance. McCoy SS; Woodham M; Bartels CM; Saldanha IJ; Bunya VY; Maerz N; Akpek EK; Makara MA; Baer AN Arthritis Rheumatol; 2022 Sep; 74(9):1569-1579. PubMed ID: 35594474 [TBL] [Abstract][Full Text] [Related]
8. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial. Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310 [TBL] [Abstract][Full Text] [Related]
9. Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren's. Cooper C; Wratten S; Williams-Hall R; Bookman AAM; Ndife B; Hueber W; Goswami P Rheumatol Ther; 2022 Dec; 9(6):1499-1515. PubMed ID: 36114443 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study. Fisher BA; Mariette X; Papas A; Grader-Beck T; Bootsma H; Ng WF; van Daele PLA; Finzel S; Noaiseh G; Elgueta S; Hermann J; McCoy SS; Akpek E; Bookman A; Sopala M; Montecchi-Palmer M; Luo WL; Scheurer C; Hueber W; Lancet; 2024 Aug; 404(10452):540-553. PubMed ID: 39096929 [TBL] [Abstract][Full Text] [Related]
11. The Florida Scoring System for stratifying children with suspected Sjögren's disease: a cross-sectional machine learning study. Zeng W; Thatayatikom A; Winn N; Lovelace TC; Bhattacharyya I; Schrepfer T; Shah A; Gonik R; Benos PV; Cha S Lancet Rheumatol; 2024 May; 6(5):e279-e290. PubMed ID: 38658114 [TBL] [Abstract][Full Text] [Related]
14. Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study. Rocca J; Beydon M; Le Guern V; Hachulla E; Couderc M; Jousse-Joulin S; Devauchelle-Pensec V; Gottenberg JE; Vittecoq O; Lavigne C; Schmidt J; Larroche C; Mariette X; Seror R; Nocturne G Lancet Rheumatol; 2024 Oct; 6(10):e703-e712. PubMed ID: 39182508 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168 [TBL] [Abstract][Full Text] [Related]
16. Development and testing of an alternative responder definition for EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI). Wratten S; Abetz-Webb L; Arenson E; Griffiths P; Bowman S; Hueber W; Ndife B; Kuessner D; Goswami P RMD Open; 2023 Mar; 9(1):. PubMed ID: 36931685 [TBL] [Abstract][Full Text] [Related]
17. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Seror R; Ravaud P; Mariette X; Bootsma H; Theander E; Hansen A; Ramos-Casals M; Dörner T; Bombardieri S; Hachulla E; Brun JG; Kruize AA; Praprotnik S; Tomsic M; Gottenberg JE; Devauchelle V; Devita S; Vollenweider C; Mandl T; Tzioufas A; Carsons S; Saraux A; Sutcliffe N; Vitali C; Bowman SJ; Ann Rheum Dis; 2011 Jun; 70(6):968-72. PubMed ID: 21345815 [TBL] [Abstract][Full Text] [Related]
18. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome. Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390 [TBL] [Abstract][Full Text] [Related]
19. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry. Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344 [TBL] [Abstract][Full Text] [Related]
20. Identification and evolution of predictors of Sjögren's disease-associated mucosa-associated lymphoid tissue lymphoma development over time: a case-control study. Goules AV; Chatzis L; Pezoulas VC; Patsouras M; Mavragani C; Quartuccio L; Baldini C; De Vita S; Fotiadis DI; Tzioufas AG Lancet Rheumatol; 2024 Oct; 6(10):e693-e702. PubMed ID: 39182505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]